These data establish the asprosin–PTPRD pair as a druggable node for metabolic syndrome amenable to both ligand‐ and receptor‐directed interventions, although high‐resolution cryo‐EM or crystallographic confirmation of the asprosin–PTPRD complex is still pending. This evidence concerns the gene FBN1 and metabolic syndrome.